

## REVIEW

## Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts

Dedee F. Murrell, MA, BMBCh, MD, FACD,<sup>a</sup> Benjamin S. Daniel, MBBS,<sup>a</sup> Pascal Joly, MD, PhD,<sup>b</sup> Luca Borradori, MD,<sup>c</sup> Masayuki Amagai, MD, PhD,<sup>d</sup> Takashi Hashimoto, MD, PhD,<sup>e</sup> Frédéric Caux, MD, PhD,<sup>f</sup> Branka Marinovic, MD, PhD,<sup>g</sup> Animesh A. Sinha, MD, PhD,<sup>h</sup> Michael Hertl, MD,<sup>i</sup> Philippe Bernard, MD, PhD,<sup>ac</sup> David Sirois, DMD, PhD,<sup>j</sup> Giuseppe Cianchini, MD,<sup>k</sup> Janet A. Fairley, MD,<sup>m</sup> Marcel F. Jonkman, MD, PhD,<sup>n</sup> Amit G. Pandya, MD,<sup>o</sup> David Rubenstein, MD, PhD,<sup>p</sup> Detlef Zillikens, MD,<sup>q</sup> Aimee S. Payne, MD, PhD,<sup>s</sup> David Woodley, MD,<sup>r</sup> Giovanna Zambruno, MD,<sup>l</sup> Valeria Aoki, MD, PhD,<sup>t</sup> Carlo Pincelli, MD,<sup>u</sup> Luis Diaz, MD,<sup>p</sup> Russell P. Hall, MD,<sup>v</sup> Michael Meurer, MD, PhD,<sup>x</sup> Jose M. Mascaró, Jr, MD,<sup>y</sup> Enno Schmidt, MD,<sup>q</sup> Hiroshi Shimizu, MD, PhD,<sup>w</sup> John Zone, MD,<sup>z</sup> Robert Swerlick, MD,<sup>ac</sup> Daniel Mimouni, MD,<sup>ad</sup> Donna Culton, MD,<sup>p</sup> Jasna Lipozencic, MD, PhD,<sup>g</sup> Benjamin Bince, MD,<sup>aa</sup> Jean-Claude Bystryń, MD,<sup>ab</sup> and Victoria P. Werth, MD<sup>s,af</sup>

*Sydney, Australia; Rouen, Bobigny, and Reims, France; Bern, Switzerland; Tokyo, Kurume, and Sapporo, Japan; Zagreb, Croatia; Buffalo and New York, New York; Marburg, Luebeck, and Dresden, Germany; Rome and Modena, Italy; Iowa City, Iowa; Groningen, The Netherlands; Dallas, Texas; Chapel Hill and Durham, North Carolina; Los Angeles, California; Philadelphia, Pennsylvania; Sao Paulo, Brazil; Barcelona, Spain; Salt Lake City, Utah; Manila, Philippines; Atlanta, Georgia; and Petah Tikva, Israel*

Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid

From the Department of Dermatology at St George Hospital, University of New South Wales, Sydney<sup>a</sup>; Clinique Dermatologique, Institut National de la Santé et de la Recherche Médicale (INSERM), INSERM U905, Rouen University Hospital, Dermatology Department, Rouen University Hospital, University of Rouen<sup>b</sup>; Department of Dermatology, University Hospital of Bern<sup>c</sup>; Keio University School of Medicine, Tokyo<sup>d</sup>; Kurume University School of Medicine<sup>e</sup>; Department of Dermatology, University of Paris XIII, Bobigny<sup>f</sup>; Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine<sup>g</sup>; Department of Dermatology, State University of New York at Buffalo, Buffalo, New York<sup>h</sup>; Department of Dermatology, University Hospital, Marburg<sup>i</sup>; Department of Oral Medicine, New York University College of Dentistry<sup>j</sup>; Immunodermatology Department<sup>k</sup> and Laboratory of Molecular and Cell Biology,<sup>l</sup> Istituto Dermopatico dell'Immacolata, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) IRCCS, Rome; Departments of Dermatology, University of Iowa and Department of Veterans Affairs Medical Center Iowa City<sup>m</sup>; University Medical Center Groningen, University of Groningen<sup>n</sup>; University of Texas Southwestern Medical Center<sup>o</sup>; Department of Dermatology, University of North Carolina, Chapel Hill<sup>p</sup>; Department of Dermatology, University of Luebeck<sup>q</sup>; Department of Dermatology, Keck School of Medicine, University of Southern California<sup>r</sup>; Department of Dermatology, University of Pennsylvania<sup>s</sup>; Department of Dermatology, University of Sao Paulo<sup>t</sup>; Institute of Dermatology, School of Biosciences and Biotechnologies, University of Modena and Reggio Emilia<sup>u</sup>; Division of Dermatology, Duke Medical Center, Durham<sup>v</sup>;

Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo<sup>w</sup>; Carl Gustav Carus Medical School, Dresden University of Technology<sup>x</sup>; Department of Dermatology, University of Barcelona<sup>y</sup>; Department of Dermatology, University of Utah<sup>z</sup>; Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila<sup>aa</sup>; New York University Medical Center<sup>ab</sup>; Department of Dermatology, Emory University School of Medicine, Atlanta<sup>ac</sup>; Department of Dermatology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel<sup>ad</sup>; Department of Dermatology, Robert Debré University Hospital, Reims<sup>ae</sup>; and Philadelphia Department of Veterans Affairs Medical Center.<sup>af</sup>

The International Pemphigus and Pemphigoid Foundation generously supported renting rooms at the American Academy of Dermatology and audiovisual equipment; the European Society for Dermatological Research and European Academy of Dermatology provided meeting rooms. This report was supported in part by a grant from the National Institutes of Health (K24-AR 02207) to Dr Werth.

Conflicts of interest: None declared.

Accepted for publication June 30, 2011.

Reprint requests: Dedee F. Murrell, MA, BMBCh, MD, FACD, Department of Dermatology, St George Hospital, University of New South Wales, Sydney, Australia. E-mail: d.murrell@unsw.edu.au.

Published online November 5, 2011.

0190-9622/\$36.00

© 2011 by the American Academy of Dermatology, Inc.

doi:10.1016/j.jaad.2011.06.032

Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies. (J Am Acad Dermatol 10.1016/j.jaad.2011.06.032.)

**Key words:** bullous pemphigoid; consensus; definitions; outcome measures; severity score.

Bullous pemphigoid (BP) is a common autoimmune bullous disease typically affecting the elderly. There have been only a handful of well-designed randomized controlled trials assessing the effectiveness of therapies for BP.<sup>1</sup> In relatively rare diseases where it is difficult to include enough patients to have sufficient power to compare different treatments, meta-analysis is a powerful tool that is used to pool data across trials. However, it is impossible to compare the therapeutic outcomes from the majority of these BP studies using meta-analysis, as they have varying definitions and outcome measures.

## PURPOSE

The purpose of this statement is to provide appropriate definitions for the various stages of disease activity, define therapeutic end points in BP, and to propose an objective disease extent measure that can be used in clinical trials. The use of the same definitions and outcome measures makes the results of trials more comparable. Since definitions and outcome measures for pemphigus<sup>2-4</sup> have been published, most trials in pemphigus and reports have begun adopting these systems or referring to them when their existing trials using other measures were unable to show a difference.<sup>5</sup>

## METHODS

An international BP definitions committee was organized in 2008, at the point when the international pemphigus definitions committee completed its similar work on pemphigus.<sup>2</sup> The committee was an expansion of the first committee and convened 7 times over 2 years to discuss the appropriate definitions. These meetings were held at the American Academy of Dermatology (AAD) annual meeting in San Antonio, TX, in 2009 (D. F. M. and V. P. W.); European Society for Dermatologic Research in

## CAPSULE SUMMARY

- It is impossible to compare the therapeutic outcomes from the majority of bullous pemphigoid studies using meta-analysis, as they have varying definitions and outcome measures.
- These recommendations, developed over the last 3 years by experts, provide appropriate definitions for the various stages of disease activity and therapeutic end points in bullous pemphigoid.
- These definitions can be used in case series and clinical trials to compare the efficacy of treatments for bullous pemphigoid.

Budapest, Hungary, in 2009 (D. F. M. and P. J.); the European Academy of Dermatovenereology in Berlin, Germany, in 2009 (D. F. M. and L. B.); the AAD in Miami, FL, in 2010 (D.F.M. and V. P. W.); the Pemphigus 2010 Meeting in Bern, Switzerland (V. P. W. and D. F. M.); and the International Pemphigus and Pemphigoid Meeting at the National Institutes of Health in November 2010 (V. P. W. and D. F. M.), in Bethesda, MD. The final meeting was held at the AAD in 2011 in New Orleans, LA (D. F. M. and V. P. W.). Meetings were sup-

ported in part by local dermatology societies. The draft definitions and end points were electronically mailed to the larger group, allowing for comments between meetings.

## THE RECOMMENDATIONS

### Observation points

The end points are illustrated and summarized (Fig 1 and Table I).

### Early end points

“Baseline” is the point at which a physician starts treatment for BP.

“Control of disease activity” (disease control; beginning of consolidation phase) is defined as the point at which new lesions or pruritic symptoms cease to form and established lesions begin to heal. The time to disease control is the time between baseline and this control point.

“End of the consolidation phase” is defined as the time at which no new lesions or pruritic symptoms have developed for a minimum of 2 weeks and the majority (approximately 80%) of established lesions has healed. At this point tapering of corticosteroids often occurs. The length of the consolidation phase is the time between disease control and the end of consolidation phase.

*Abbreviations used:*

AAD:	American Academy of Dermatology
BP:	bullous pemphigoid
BPDAI:	Bullous Pemphigoid Disease Area Index
DAI:	Disease Area Index
PDAI:	Pemphigus Disease Area Index

“Transient lesions” are new lesions that heal within 1 week or pruritus lasting less than a week and clearing without treatment.

“Nontransient lesions” are new lesions that do not heal within 1 week or pruritus continuing more than a week with or without treatment.

**Intermediate end points**

During this period, the corticosteroids and other treatments are usually being tapered, but for some patients medication doses do not change because of flaring with attempts to taper treatment. “Complete remission during tapering” is the absence of nontransient lesions while the patient is receiving more than minimal therapy. There is no minimum time point here as the patient is under control but has not yet reached the desired outcome of disease remission on minimal or no therapy.

**Late observation end points**

Late observation end points of disease activity are identified as: (1) complete remission off therapy; and (2) complete remission on therapy, both of which only apply to patients who have had no new or established lesions for at least 2 months. “Complete remission off therapy” is defined as an absence of new or established lesions or pruritic symptoms while the patient is off all BP therapy for at least 2 months.



“Complete remission on therapy” is defined as the absence of new or established lesions or pruritus while the patient is receiving *minimal* therapy for at least 2 months. “Minimal therapy” is defined as less than or equal to 0.1 mg/kg/d of prednisone (or the equivalent) or 20 g/wk of clobetasol propionate and/or minimal adjuvant or maintenance therapy for at least 2 months, as shown in Fig 1 and discussed further below.

Minimal adjuvant therapy in BP corresponds to the following doses or less: methotrexate 5 mg/wk; azathioprine 0.7 mg/kg/d (with normal thiopurine s-methyltransferase level); mycophenolate mofetil 500 mg/d; mycophenolic acid 360 mg/d; or dapsone 50 mg/d. There has only been one small randomized controlled trial on tetracycline and niacinamide,<sup>6</sup> which was underpowered because of low numbers and was unable to demonstrate a difference. Nevertheless, the committee’s expert opinion is that full therapeutic doses of the tetracyclines may work in localized forms of BP. As the tetracycline class of drugs is relatively nontoxic, the full therapeutic dose was listed among minimal therapies for BP.

“Partial remission off therapy” is defined as the presence of transient new lesions that heal within 1 week without treatment and while the patient is off all BP therapy for at least 2 months.

“Partial remission on minimal therapy” is defined as the presence of transient new lesions that heal within 1 week while the patient is receiving minimal therapy.

A newer term, “mild new activity,” refers to fewer than 3 lesions a month (blisters, eczematous lesions, or urticarial plaques) that do not heal within 1 week, or the extension of established lesions or pruritus once per week but less than

**Early and intermediate observation points****Late observation endpoints**

**Fig 1.** Pictorial depiction of end points in bullous pemphigoid.

**Table I.** Definitions for bullous pemphigoid

<b>Early observation points</b>	
Baseline	Day that BP therapy is started by physician
Control of disease activity	Time at which new lesions cease to form and established lesions begin to heal or pruritic symptoms start to abate
Time to control of disease activity (disease control; beginning of consolidation phase)	Time interval from baseline to control of disease activity
End of consolidation phase	Time at which no new lesions have developed for minimum of 2 wk and approximately 80% of lesions have healed and pruritic symptoms are minimal
<b>Intermediate observation end points</b>	
Transient lesions	New lesions that heal within 1 wk or pruritus lasting <1 wk and clearing without treatment
Nontransient lesions	New lesions that do not heal within 1 wk or pruritus continuing >1 wk with or without treatment
Complete remission during tapering	Absence of nontransient lesions while patient is receiving more than minimal therapy
<b>Late observation end points</b>	
Minimal therapy	≤ 0.1 mg/kg/d Of prednisone (or equivalent) or 20 g/wk of clobetasol propionate and/or minimal adjuvant or maintenance therapy
Minimal adjuvant therapy and/or maintenance therapy	Following doses or less: methotrexate 5 mg/wk; azathioprine 0.7 mg/kg/d (with normal thiopurine s-methyltransferase level); mycophenolate mofetil 500 mg/d; mycophenolic acid 360 mg/d; or dapsone 50 mg/d
Partial remission on minimal therapy	Presence of transient new lesions that heal within 1 wk while patient is receiving minimal therapy for at least 2 mo
Complete remission on minimal therapy	Absence of new or established lesions or pruritus while patient is receiving minimal therapy for at least 2 mo
Partial remission off therapy	Presence of transient new lesions that heal within 1 wk without treatment while patient is off all BP therapy for at least 2 mo
Complete remission off therapy	Absence of new or established lesions or pruritus while patient is off all BP therapy for at least 2 mo
Mild new activity	<3 Lesions/mo (blisters, eczematous lesions, or urticarial plaques) that do not heal within 1 wk, or extension of established lesions or pruritus once/wk but less than daily in patient who has achieved disease control; these lesions have to heal within 2 wk
Relapse/flare	Appearance of ≥ 3 new lesions/mo (blisters, eczematous lesions, or urticarial plaques) or at least one large (>10 cm diameter) eczematous lesion or urticarial plaques that do not heal within 1 wk, or extension of established lesions or daily pruritus in patient who has achieved disease control
Failure of therapy for initial control	Development of new nontransient lesions or continued extension of old lesions, or failure of established lesions to begin to heal or continued pruritus despite: Clobetasol propionate 40 g/d for 4 wk; or Prednisone 0.75 mg/kg/d equivalent for minimum of 3 wk with or without drugs used for maintenance therapy; or A tetracycline on full dosing for 4 wk; or Dapsone 1.5 mg/kg/d for 4 wk; or Methotrexate 15 mg/wk (if >60 kg and no major renal impairment) for 4 wk; or Azathioprine 2.5 mg/kg/d for 4 wk (if thiopurine s-methyltransferase level is normal); or Mycophenolate mofetil 40 mg/kg/d (if normal renal function, otherwise according to age/creatinine clearance) for 4 wk

BP, Bullous pemphigoid.

daily, in a patient who has achieved disease control. This term was not included in the pemphigus definitions but the committee thought that it might be important to capture this phase during studies to determine if some patients with BP and certain

characteristics or treatments experienced new mild activity not significant enough to constitute a flare. In this way, it could be determined in the future if these patients with BP might benefit from a change of treatment plan or not.



**Relapse/flare**

The terms “relapse” and “flare” are used interchangeably and are defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least one large (>10 cm diameter) eczematous lesion or urticarial plaque that does not heal within 1 week, or the extension of established lesions or daily pruritus in a patient who has achieved disease control.

**Treatment failure**

“Failure of therapy for initial control” is defined as the development of new nontransient lesions or continued extension of old lesions, or failure of established lesions to begin to heal or daily pruritus despite certain strengths of corticosteroids with or without higher doses of adjuvants. The dose of prednisone defined as treatment failure is 0.75 mg/kg/d equivalent for minimum of 3 weeks. This dose was selected because the Cochrane review of interventions for BP<sup>1,7</sup> determined that in acute BP there was no purpose in using prednisone at a higher dose than this. Topical clobetasol propionate at 40 g/d for 4 weeks was selected on the basis of the randomized controlled trials conducted by the French group.<sup>8,9</sup> Other therapies include tetracycline at full doses for 4 weeks; dapsone 1.5 mg/kg/d for 4 weeks; methotrexate 15 mg/wk (if >60 kg and no major renal impairment) for 4 weeks; azathioprine 2.5 mg/kg/d for 4 weeks (if thiopurine s-methyltransferase level is normal); or mycophenolate mofetil 40 mg/kg/d (if normal renal function, otherwise according to age/creatinine clearance) for 4 weeks. The definition does not imply these drugs and their respective doses are equivalent in therapeutic efficacy. Rather it provides a standardized agreement as to what can be defined as a failure of therapy.

**BP disease activity index**

Like the Pemphigus Disease Area Index (PDAI),<sup>3</sup> the BP Disease Area Index (BPDAI) measure has separate scores for skin and mucous membrane activity. Damage scores are separate as well and are included to remind physicians that not all visible lesions in BP represent active disease. Areas of the skin predominantly affected in BP<sup>10</sup> were taken into account when selecting the skin sites so that trials would better differentiate clinical response in BP. Hence, additional weighting was given to the arms and legs and less emphasis to the face and scalp, slightly different from the PDAI. The mucous membrane areas were retained from the PDAI even though it is relatively rare to see mucous membrane involvement in BP, so that the activity could be

**BPDAI PRURITUS COMPONENT - VAS**

DATE: .....

Baseline
  Beginning Consolidation  
 Consolidation phase
  End of Consolidation  
 Tapering phase
  Partial remission on minimal therapy  
 Complete remission on minimal therapy
  Partial remission off therapy  
 Complete remission off therapy
  Flare

**A. How severe has your itching been over the last 24 hours?**

0 1 2 3 4 5 6 7 8 9 10  
None Severe

Score out of 10 =

**B. How severe has your itching been the past week?**

0 1 2 3 4 5 6 7 8 9 10  
None Severe

Score out of 10 =

**C. How severe has your itching been in the past month?**

0 1 2 3 4 5 6 7 8 9 10  
None Severe

Score out of 10 =

Average INTENSITY SCORE FOR PAST MONTH = (A+B+C) =

OR

For BP patients with impaired mental functioning:

No evidence of itch (no excoriations)	0
Mild itch (isolated excoriations up to two body sites)	10
Moderate itch (excoriations on ≥ 3 body sites, impairment of daily activity)	20
Severe itch (generalized excoriation, sleep impairment)	30
<b>TOTAL SCORE</b>	<b>/30</b>

**Fig 2.** Subjective Bullous Pemphigoid (BP) Disease Area Index (BPDAI) pruritus score. VAS, Visual analog scale.

compared with extent of mucous membrane involvement in different autoimmune bullous diseases. There are separate columns for the extent of blistering and for the urticarial/eczematous lesions that may be more extensive in BP.

As a major symptom that may herald the onset and recurrence of BP is pruritus, a separate subjective component of the BPDAI is proposed to measure the severity of this (Fig 2). Naturally, other causes of pruritus in the elderly must be excluded, such as xerosis, dermatitis, renal impairment, liver impairment, and scabies. Providing that only pruritus related to BP is considered in the definitions and scored, this system can be used to subjectively grade the intensity of pruritus using a visual analog scale to answer the question, “How severe is your itching today?” and the patient marks an “x” on the 0- to 10-cm line where 0 is no itch and 10 is maximal itching. The degree of itching is measured as the distance in centimeters from 0, out of 10. This is repeated for the severity overall of itching in the past week and month. A total score is calculated from this out of 30. If the patient with BP is incapable of completing a reliable visual analog scale rating, for example, as a result of dementia, then the degree of pruritus is inferred, based on the extent of excoriations alone, also scored

BPDAI					
SKIN	ACTIVITY		ACTIVITY		DAMAGE
Anatomical location	Erosions/Blisters	Number of Lesions if <3	Urticaria/ Erythema / Other	Number of Lesions if <3	Pigmentation / Other
	0 absent		0 absent		Absent 0, present 1
	1 1-3 lesions, none > 1 cm diameter		1 1-3 lesions, none >6 cm diameter		
	2 1-3 lesions, at least one > 1 cm diameter		2 1-3 lesions, at least one lesion > 6 cm diameter		
	3 >3 lesions, none > 2 cm diameter		3 >3 lesions, or at least one lesion > 10 cm		
	5 >3 lesions, and at least one >2 cm		5 >3 lesions and at least one lesion > 25 cm		
	10 >3 lesions, and at least one lesion >5 cm diameter or entire area		10 >3 lesions and at least one lesion > 50 cm diameter or entire area		
Head					
Neck					
Chest					
Left arm					
Right arm					
Hands					
Abdomen					
Genitals					
Back/Buttocks					
Left leg					
Right leg					
Feet					
Total skin	/120		/120		
MUCOSA	Erosions/Blisters				
	1 1 lesion				
	2 2-3 lesions				
	5 >3 lesions, or 2 lesions >2cm				
	10 entire area				
Eyes					
Nose					
Buccal mucosa					
Hard palate					
Soft palate					
Upper gingiva					
Lower gingiva					
Tongue					
Floor of Mouth					
Labial Mucosa					
Posterior Pharynx					
Anogenital					
Total Mucosa	/120				

Fig 3. Objective bullous pemphigoid disease area index

out of 30 (Fig 2). This subjective itch score will not be combined with the objective part of the BPDAI (Fig 3). Eventually, a quality-of-life tool for BP will be necessary as well. The BPDAI will be undergoing validation studies, similar to the partial validation done thus far with the PDAI.<sup>3</sup>

**DISCUSSION AND CONCLUSION**

Despite many trials evaluating therapeutic options for BP, it has been difficult to compare the results from these trials because of the large number of end points and definitions of disease. The formation of an international committee of bullous

disease experts able to meet face to face on a regular basis has provided a mechanism for developing agreement on these issues for BP. This statement with agreed-upon common definitions, and the ongoing discussion and refinement of proposed common measurements for patients with BP, are the initial and necessary steps toward progress in the clinical evaluation and therapy of BP. Further progress and advancement will require a continued unified effort.

The following individuals who were unable to attend the meetings contributed by e-mail to the discussions: Cheyda Chams-Davatchi, Karen Harman, Pilar Iranzo, and Gudula Kirtschig. Molly Stuart and Will Zmchik at the International Pemphigus and Pemphigoid Foundation assisted with meeting setup.

#### REFERENCES

1. Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. *Cochrane Database Syst Rev* 2010;10:CD002292.
2. Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. *J Am Acad Dermatol* 2008;58:1043-6.
3. Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, et al. Reliability and convergent validity of two outcome instruments for pemphigus. *J Invest Dermatol* 2009;129:2404-10.
4. Pflutze M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. *Eur J Dermatol* 2007;17:4-11.
5. Fiorentino DF, Garcia MS, Rehmus W, Kimball AB. A pilot study of etanercept treatment for pemphigus vulgaris. *Arch Dermatol* 2011;147:117-8.
6. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. *Arch Dermatol* 1994;130:753-8.
7. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day; a multicenter randomized study. *Ann Dermatol Venereol* 1984; 111:925-8.
8. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. *N Engl J Med* 2002;346:321-7.
9. Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. *J Invest Dermatol* 2009;129:1681-7.
10. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions; Bullous Diseases French Study Group. *Arch Dermatol* 1995; 131:48-52.

### Childhood subepidermal blistering disease with autoantibodies to type VII collagen and laminin-332

DOI: 10.1111/j.1365-2133.2010.10065.x

MADAM, Autoimmune subepidermal blistering diseases include bullous pemphigoid, pemphigoid gestationis, linear IgA bullous dermatosis, mucous membrane pemphigoid (MMP), anti-p200 pemphigoid, epidermolysis bullosa acquisita (EBA) and bullous systemic lupus erythematosus.<sup>1</sup> Patients with EBA have IgG autoantibodies to type VII collagen while some patients with MMP have autoantibodies to laminin-332.<sup>2,3</sup> We describe a juvenile case of subepidermal blistering disease with autoantibodies to both type VII collagen and laminin-332. The present case is unique because of its childhood onset and successful remission following only topical steroid therapy.

A 12-year-old Japanese girl presented with pruritic eruptions on her scalp. A few weeks later, widespread pruritic vesicles gradually developed over her whole body. The vesicles were seen both on erythematous and normal skin (Fig. 1a, b). Blisters and erosions also appeared in her oral mucosa, but there was no involvement of genital or ocular mucous membranes (Fig. 1c).

Neither nail changes nor alopecia were observed. She had no family history of any blistering disorders or autoimmune disease. There was no preceding illness or history of medication/vaccination that might have triggered her disease.

General laboratory examinations revealed no apparent abnormalities except for an increased serum IgE level (668.8 IU mL<sup>-1</sup>; normal < 100 for age 7–14 years). A skin biopsy was taken from the edge of one blister on her right forearm. Light microscopy showed a subepidermal blister with an inflammatory cell infiltrate consisting of mainly neutrophils in the upper dermis (Fig. 2a). Direct immunofluorescence of the patient's lesional skin showed *in vivo* linear deposits of IgG and C3 at the epidermal basement membrane zone (Fig. 2b). On the blistered area, deposition of IgG and C3 was demonstrated on the dermal side of the separated skin (arrows, Fig. 2b). Indirect immunofluorescence with the patient's serum on 1 mol L<sup>-1</sup> NaCl-split normal human skin showed IgG antibodies bound to the dermal side of the blister (Fig. 2c). Immunoblot analysis revealed that the patient's serum reacted with a 290-kDa protein in dermal extracts, and further with purified laminin-332  $\alpha$ 3 protein (145, 165 kDa) (Fig. 2d, e). Laminin-332 was obtained from human keratinocytes and was purified using an antilaminin-332 affinity column as




Fig 1. Clinical manifestations of the skin and oral mucosa. (a–c) Before topical steroid therapy. Erythema and tense vesicles on the left forearm and chest (a and b, arrows). Blisters and erosions over the oral mucosa (c, arrows). (d–f) After topical steroid therapy. Skin lesions healed within 9 days of the beginning of treatment, leaving residual pigmentation, scars and milia (d and e). Blisters and erosions on the oral mucosa subsided (f, arrow).




Fig 2. Histopathological findings, immunofluorescence staining and immunoblot analyses. (a) A subepidermal blister with an inflammatory cell infiltrate composed of mainly neutrophils in the upper dermis (haematoxylin and eosin; original magnification  $\times 40$ ). (b) Direct immunofluorescence showed *in vivo* linear deposits of IgG along the basement membrane zone. On the blister area, deposition of IgG was shown to be towards the dermal side of separated skin (arrows) (original magnification  $\times 40$ ; white dotted line is the skin surface and red dotted line is the roof side of separated skin). (c) Indirect immunofluorescence with the patient's serum on  $1 \text{ mol L}^{-1}$  NaCl-split normal human skin showed IgG antibodies bound to the dermal side (arrows) (original magnification  $\times 40$ ). (d) Immunoblot analysis revealed that the patient's serum (lane 1), like both serum from a reference patient with epidermolysis bullosa acquisita (EBA, lane 2) and monoclonal antibody LH7.2 to type VII collagen (lane 3), reacted with a 290-kDa protein in dermal extracts (arrowhead). Control anti-p200 serum did not react with the 290-kDa but with a 200-kDa protein (red arrowhead) (lane 4). Normal control serum (lane 5) showed reactivity with neither. (e) In immunoblotting of purified laminin-332, lane 1 shows Ponceau S stain (protein staining using amido black). Reactivity with 145-kDa and 165-kDa purified laminin-332  $\alpha 3$  protein (arrowheads) was indicated in the patient's serum (lane 2), but not in the normal control serum (lane 3).

previously described.<sup>4,5</sup> Purified laminin-332 was a generous gift from Dr S. Amano, Shiseido Life Science Research Centre, Yokohama, Japan. The patient was diagnosed as having an autoimmune subepidermal blistering disease with circulating autoantibodies to type VII collagen and laminin-332.

Treatment was initiated with 0.05% clobetasol propionate ointment 20 g daily to skin lesions, which healed within 9 days after the beginning of treatment, leaving residual pigmentation, scars and milia (Fig. 1d, e). Blisters and erosions on the oral mucosa subsided without any topical therapy (Fig. 1f). The dose of topical corticosteroids was progressively decreased, and no recurrence of skin lesions was observed. The titre of antibasement membrane zone antibodies in indirect immunofluorescence studies decreased from 1 : 320 to 1 : 40 over 2 months. We performed further immunoblot analyses on five serial serum samples obtained from the patient after her antibasement membrane zone antibodies decreased. All five samples showed similar reaction bands to both 290-kDa protein in dermal extracts and purified laminin-332  $\alpha 3$  protein (145, 165 kDa) (data not shown). Hence it is difficult to speculate the major target antigen in this patient from these results. No local or systemic side-effects of topical corticosteroids were noticed during the entire treatment duration.

EBA and MMP are distinct autoimmune bullous diseases that are both characterized by autoantibodies to dermoepi-

dermal junction components.<sup>1</sup> Detection of autoantibodies to either type VII collagen or laminin-332 differentiates these two diseases.<sup>1</sup> Interestingly, besides antitype VII collagen antibodies, circulating antilaminin-332  $\alpha 3$  antibodies were also found in our patient's serum. According to our survey of the literature, three other previous cases of subepidermal blistering disease with circulating antibodies to both type VII collagen and antilaminin-332 have been reported (Table 1).<sup>6-8</sup> All of the reported cases are of adult onset, thus our report is the first juvenile case. Similar to our patient, these reported patients all presented with mucosal involvement.

Our case is unique in its course and prognosis as well as age at onset. All of the previously reported patients needed systemic corticosteroids or immunosuppressant agents for proper disease control. In the studies by Jonkman *et al.*<sup>6</sup> and Umemoto *et al.*,<sup>7</sup> the bullous lesions of the patients relapsed after systemic prednisolone was tapered. The skin lesions of the patient reported by Baican *et al.*<sup>8</sup> were refractory to systemic prednisolone, azathioprine and dapsone. However, our juvenile case was successfully treated with only topical steroids, and no recurrence was observed in the following 6 months. Our case suggests that the treatment outcome and prognosis of juvenile cases are better than those of adult-onset cases. Further accumulation of similar juvenile cases is needed to confirm this hypothesis. The differ-

Table 1 Comparison of four reported patients with circulating antitype VII collagen and antilaminin-332 antibodies

Patient	Age (years)/sex	Skin lesion	Mucosal involvement	Treatment	Outcome	Immunoblot analysis	Reference
1	64/F	Blisters and erythema on the hands and feet	Oral/genital	Oral prednisolone 80 mg daily	Lesions resolved without scars/milia. Mild relapse occurred when tapering to oral prednisolone 5 mg daily	Type VII collagen, laminin-332 $\alpha 3$	Jonkman et al. <sup>6</sup>
2	46/M	Erythematous plaque, blisters, erosions and crusts on the trunk and extensor aspects of extremities	Oral	Oral colchicine 1.5 mg daily (refractory to prednisolone, azathioprine and dapsone)	Previous lesions healed with milia and scars. Free of new blisters but erythematous plaque persisted with erosions and crusts	Type VII collagen, laminin-332 $\alpha 3, \gamma 2$	Baicán et al. <sup>8</sup>
3	35/F	Vesicular lesions on the face, neck and upper back	Oral/genital	Oral prednisolone 40 mg daily	Lesions resolved without scars/milia. Mild relapse occurred when tapering to oral prednisolone 2.5 mg daily	Type VII collagen, laminin-332 $\alpha 3, \beta 3$	Umamoto et al. <sup>7</sup>
4	12/F	Blisters, erosions and erythema on the face, trunk, hands and feet	Oral	Topical clobetasol propionate ointment 20 g daily	Lesions resolved with scars and milia. No recurrence was found	Type VII collagen, laminin-332 $\alpha 3$	Our patient

ences between childhood-onset and adult-onset cases seem to mirror those of EBA at different ages. Compared with adult cases, childhood EBA cases respond relatively better to treatment, and usually low-dose oral prednisolone and dapsone are effective and sufficient.<sup>1</sup>

In conclusion, we report the first juvenile case with autoantibodies to both type VII collagen and laminin-332, successfully treated with only topical steroid therapy. Our case suggests that juvenile cases have different characteristics from those of adult-onset cases in their course, including treatment outcome and prognosis. As topical steroid therapy has several advantages over systemic corticosteroids due to less severe complications, we consider topical steroids as preferable to systemic steroids for childhood-onset autoimmune subepidermal bullous disease.

Department of Dermatology,  
Hokkaido University Graduate School  
of Medicine, Sapporo, Japan  
Correspondence: Teruki Yanagi.  
E-mail: yanagi@med.hokudai.ac.jp

H.-Y. LIN  
T. YANAGI  
M. AKIYAMA  
M.M. IITANI  
R. MORIUCHI  
K. NATSUGA  
S. SHINKUMA  
N. YAMANE  
D. INOKUMA  
K. ARITA  
H. SHIMIZU

## References

- 1 Fine JD. Management of acquired bullous skin diseases. *N Engl J Med* 1995; **333**:1475–84.
- 2 Mayuzumi M, Akiyama M, Nishie W et al. Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: case report and review of the literature. *Br J Dermatol* 2006; **155**:1048–52.
- 3 Domloge-Hultsch N, Anhalt GJ, Gammon WR et al. Anti-epiligrin cicatricial pemphigoid: a subepithelial bullous disorder. *Arch Dermatol* 1994; **130**:1521–9.
- 4 Natsuga K, Nishie W, Shinkuma S et al. Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid. *Br J Dermatol* 2010; **162**:513–17.
- 5 Amano S, Nishiyama T, Burgeson RE. A specific and sensitive ELISA for laminin 5. *J Immunol Methods* 1999; **224**:161–9.
- 6 Jonkman MF, Schuur J, Dijk F et al. Inflammatory variant of epidermolysis bullosa acquisita with IgG autoantibodies against type VII collagen and laminin alpha3. *Arch Dermatol* 2000; **136**:227–31.
- 7 Umamoto N, Demitsu T, Toda S et al. A case of nonscarring subepidermal blistering disease associated with autoantibodies reactive with both type VII collagen and laminin 5. *Dermatology* 2003; **207**:61–4.
- 8 Baicán A, Hirako Y, Lazarova Z et al. IgG antibodies to type VII collagen and an exclusive IgG3 reactivity to the laminin alpha3 chain in a patient with an autoimmune subepidermal blistering disease. *J Am Acad Dermatol* 2005; **53**:517–22.

Funding sources: none.

Conflicts of interest: none declared.

# Abca12-mediated lipid transport and Snap29-dependent trafficking of lamellar granules are crucial for epidermal morphogenesis in a zebrafish model of ichthyosis

Qiaoli Li<sup>1,\*</sup>, Michael Frank<sup>1,\*</sup>, Masashi Akiyama<sup>2,3</sup>, Hiroshi Shimizu<sup>3</sup>, Shiu-Ying Ho<sup>4</sup>, Christine Thisse<sup>5</sup>, Bernard Thisse<sup>5</sup>, Eli Sprecher<sup>6</sup> and Jouni Uitto<sup>1,4,‡</sup>

## SUMMARY

Zebrafish (*Danio rerio*) can serve as a model system to study heritable skin diseases. The skin is rapidly developed during the first 5-6 days of embryonic growth, accompanied by expression of skin-specific genes. Transmission electron microscopy (TEM) of wild-type zebrafish at day 5 reveals a two-cell-layer epidermis separated from the underlying collagenous stroma by a basement membrane with fully developed hemidesmosomes. Scanning electron microscopy (SEM) reveals an ordered surface contour of keratinocytes with discrete microridges. To gain insight into epidermal morphogenesis, we have employed morpholino-mediated knockdown of the *abca12* and *snap29* genes, which are crucial for secretion of lipids and intracellular trafficking of lamellar granules, respectively. Morpholinos, when placed on exon-intron junctions, were >90% effective in preventing the corresponding gene expression when injected into one- to four-cell-stage embryos. By day 3, TEM of *abca12* morphants showed accumulation of lipid-containing electron-dense lamellar granules, whereas *snap29* morphants showed the presence of apparently empty vesicles in the epidermis. Evaluation of epidermal morphogenesis by SEM revealed similar perturbations in both cases in the microridge architecture and the development of spicule-like protrusions on the surface of keratinocytes. These morphological findings are akin to epidermal changes in harlequin ichthyosis and CEDNIK syndrome, autosomal recessive keratinization disorders due to mutations in the *ABCA12* and *SNAP29* genes, respectively. The results indicate that interference of independent pathways involving lipid transport in the epidermis can result in phenotypically similar perturbations in epidermal morphogenesis, and that these fish mutants can serve as a model to study the pathomechanisms of these keratinization disorders.

## INTRODUCTION

### Clinical and genetic heterogeneity of ichthyosis

Ichthyosis comprises a group of both acquired and heritable keratinization disorders characterized by hyperkeratotic and scaly skin (Brown and Irvine, 2008). Although the phenotypic spectrum of ichthyosiform dermatoses is extremely broad, with either limited or extensive involvement of the skin, among the inherited forms, three clinically and genetically distinct subtypes have been identified: ichthyosis vulgaris, X-linked ichthyosis and lamellar ichthyosis (LI) (McGrath and Uitto, 2008; Brown and Irvine, 2008;

Brown and McLean, 2008; Elias et al., 2004). LI in itself is a heterogeneous group of autosomal recessive disorders with large plaque-like brown scales over most of the body, associated with ectropion and alopecia.

Harlequin ichthyosis (HI) is a rare, extremely severe form of ichthyosis, most closely associated with the LI group of these disorders (Akiyama, 2006a). Neonates are born encased in a thick skin that not only restricts their movement, but also distorts their facial features, averting their lips and eyelids. Although newborns with HI frequently die within the first few days of life, a few of these affected individuals do survive, and their skin eventually resembles severe non-bullous congenital ichthyosiform erythroderma or LI.

HI is an autosomal recessive disorder caused by mutations in the ATP-binding cassette, sub-family A, member 12 (*ABCA12*) gene, which encodes a lipid transporter protein localized to lamellar granules in epidermal keratinocytes (Sakai et al., 2007). Mutations in the *ABCA12* gene result in congested lipid secretion and impaired barrier function of the stratum corneum (Kelsell et al., 2005). Thus, *ABCA12* is crucial to the development of the skin-lipid barrier in the stratum corneum.

An *Abca12*<sup>-/-</sup> mouse model has been vital in confirming the role of this transporter molecule in the skin abnormalities seen in HI, i.e. hyperkeratosis, impaired barrier function, abnormal lamellar bodies and the retention of lipid droplets in the epidermis (Yanagi et al., 2008; Smyth et al., 2008; Sundberg et al., 1997). The role of *Abca12* in transporting lipids was confirmed by culturing keratinocytes from *Abca12*<sup>-/-</sup> mice and observing impaired lipid

<sup>1</sup>Department of Dermatology and Cutaneous Biology, and <sup>4</sup>Department of Biochemistry and Molecular Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

<sup>2</sup>Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

<sup>3</sup>Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

<sup>5</sup>Department of Cell Biology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA

<sup>6</sup>Department of Dermatology, Tel Aviv Medical Center, Tel Aviv 64239, Israel


\*These authors equally contributed to this work

‡Author for correspondence (Jouni.uitto@jefferson.edu)

Received 29 October 2010; Accepted 27 May 2011

© 2011. Published by The Company of Biologists Ltd  
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (<http://creativecommons.org/licenses/by-nc-sa/3.0>), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.





**Fig. 1. Schematic representation of the zebrafish *abca12* gene, and the phylogenetic trees of the protein sequences of *Abca12* and *Snap29*, together with syntenic analysis of the corresponding genes.** (A) The *abca12* gene consists of 53 exons, which are numbered on the top, and the coding segments for transmembrane domains (TMDs) and nucleotide binding folds (NBFs; green) are underlined. Note the location corresponding to the morpholino (MO1) at the exon-4–intron-4 junction. (B) The phylogenetic relationship between zebrafish *Abca12* and the other members of the ABC family of transporters estimated by the neighbor-joining method (left panel). The syntenic analysis of the *abca12* and flanking genes in human, mouse, zebrafish and chicken chromosomes is shown on right. (C) Cladogram and syntenic analysis of *snap29*. The unknown genes 1 and 2 in zebrafish chromosome 8 have been designated as *sid:key-178e17.1* and *sid:key-117b11.1*, respectively.

Disease Models & Mechanisms • DMM

efflux leading to intracellular accumulation of lipids, specifically ceramides (Akiyama et al., 2005). However, the drawback of the mouse model is the long gestation period and small number of offspring per litter.

In addition to nonsyndromic variants, ichthyosis can be associated with clinical manifestations in a number of organ systems besides the skin. An example of syndromic ichthyoses is the CEDNIK syndrome, a rare autosomal recessive disorder with cerebral dysgenesis, neuropathy, ichthyosis and keratoderma. This syndrome has been shown to be associated with mutations in the *SNAP29* gene, which encodes soluble n-ethylmaleimide sensitive factor (NSF) attachment protein (SNAP)29, a member of the SNAP receptor (SNARE) family of proteins (Sprecher et al., 2005; Fuchs-Telem et al., 2011). SNARE proteins are required for vesicle trafficking and they mediate the fusion between the vesicles and their target membranes. *SNAP29* deficiency has been suggested to result in impaired maturation and secretion of lamellar granules, particularly interfering with the transport of lipids to stratum corneum; however, no animal model for the CEDNIK syndrome exists.

In an attempt to create an alternative, and perhaps more expedient, model system to study ichthyosis, we have performed work on zebrafish (*Danio rerio*), which has nearly the same complement of genes as mammals. Some of the benefits to working with zebrafish include their rapid development and the ease with which one can manipulate their gene expression by morpholino-based antisense

oligonucleotides (Kari et al., 2007; Li et al., 2011). Zebrafish develop rapidly, with all major organs, including the skin, having developed by 5–6 days post-fertilization (dpf). They also produce a large number of embryos per laying, approximately 50–100 per female. In this study, we performed experiments to show that *abca12* and *snap29* gene knockdown in zebrafish causes epidermal changes that are similar, attesting to the concept that diverse pathogenetic pathways, as a result of mutations in different genes, can result in phenotypes in the spectrum of ichthyotic diseases. Thus, zebrafish provide a novel and expedient model system to study this group of devastating, currently intractable, diseases.

**RESULTS**

**Identification of an *ABCA12*-related gene in the zebrafish genome**

Search of the online gene database (NCBI) identified one human *ABCA12*-related sequence, *abca12*, which mapped to zebrafish chromosome 9. This zebrafish *abca12* gene had an open reading frame, and all splice sites appeared intact, which allowed deduction of the intron-exon organization. The *abca12* gene consists of 53 exons, with sizes ranging from 55 to 2415 bp (Fig. 1A). The predicted primary sequence of the corresponding protein consists of 3634 amino acids, whereas the corresponding human primary sequence comprises 2595 amino acids. The overall conservation at the protein level was 49.3% and, consequently, the zebrafish *abca12* gene can be considered to be the human *ABCA12* homolog.

Alignment of human and zebrafish protein sequences revealed that zebrafish *Abca12* has an extended 486 amino acid N-terminal sequence, as well as a number of insertions in the N-terminal half of the protein. However, alignment of zebrafish and human sequences identified conservation of domains that are characteristic of the ABC transporter proteins. Specifically, the zebrafish sequence, similar to the human sequence, was predicted to consist of four transmembrane domains (TMD1-4) and to contain two nucleotide binding fold domains (NBF1 and NBF2) (Tusnády et al., 2006) (Fig. 1A). The NBFs displayed characteristic sequences for Walker A and B motifs, as well as a highly conserved ABC signature sequence. Comparison of the deduced amino acid sequence within the NBF1 domain of zebrafish *Abca12* showed 74% identity to the corresponding NBF1 domain in the human protein, whereas the NBF2 domain had 68% identity to human NBF2.

### Evolutionary conservation of zebrafish *abca12*


Differences between the zebrafish *abca12* gene and homologous genes in other species were examined by phylogenetic analysis of the corresponding protein sequence by cladistic measurement (Fig. 1B). The cladogram suggested that the zebrafish gene is distant from most of the other *ABCA12*-related genes in a number of species, and, therefore, presumably diverged early. However, inclusion of other members of the ABC transporter family, such as *ABCC10* and *ABCC6*, in different species, serving as an outgroup, indicated that the zebrafish *Abca12* protein sequence is closer to human *ABCA12* than it is to the sequences in the outgroup. To confirm that the zebrafish *abca12* is the correct ortholog of human *ABCA12*, syntenic analysis of *Abca12* in different species was performed (Fig. 1B). These analyses revealed that *ABCA12* and its flanking genes, *VWC2L* and *BARD1*, were located on the same chromosome in the same gene order in human, mouse, zebrafish and chicken genomes (Fig. 1B).

### Expression of the zebrafish *abca12* gene during early embryonic development

The temporal expression profile of *abca12* was examined in embryos collected during the first 8 days of development, and the corresponding mRNA levels were determined by reverse transcriptase (RT)-PCR. An undetectable level of expression was noted in embryos at the time of fertilization [0 hours post-fertilization (hpf)], but detectable levels of mRNA transcripts were noted at 6 hpf, with a significant further increase by 1 dpf. During the subsequent days (2-8 dpf), the expression levels remained relatively constant in comparison with the control gene, *β-actin* (Fig. 2A).

### Whole-mount in situ hybridization of *abca12* in zebrafish

To determine the spatial expression of *abca12* during different stages of zebrafish development, whole-mount in situ hybridization was performed using probes specific for the *abca12* gene (Fig. 2B). An antisense probe for *abca12* gave specific expression patterns. During the gastrula period, expression of *abca12* was observed in cells of the enveloping layer (EVL; Fig. 2B). Expression of the *abca12* gene in this tissue, which is named periderm after the end of gastrulation, is observed until the end of embryonic development. After 24 hpf, expression of *abca12* was also observed, although at lower levels, in the olfactory vesicle as well as in mucus-secreting



**Fig. 2. *abca12* and *snap29* gene expression in normal zebrafish.**


(A-C) Zebrafish embryos were collected at 0 and 6 hpf and 1-8 dpf, and total RNA was isolated and cDNA prepared. The *abca12* (A) and *snap29* (C) mRNA expression levels were measured by RT-PCR and standardized against the mRNA expression level of the  $\beta$ -actin gene. (B) Whole-mount in situ hybridization of embryos at different stages of early development for *abca12* expression; gastrula period (left panel), 24 hpf (right panel).

cells (Fig. 2B). At the end of embryonic development, expression was observed mainly in olfactory vesicle, pharynx and mucus-secreting cells. A sense probe was used as a control and did not give a specific expression pattern.

### Morpholino knockdown of *abca12* expression results in an altered skin phenotype

Morpholino antisense oligonucleotide (MO1) directed against a splice donor site in *abca12* was injected into one- to four-cell-stage embryos, and amplification of total RNA was performed by primers corresponding to exons 4 and 5. Using these primers, PCR amplification of *abca12* cDNA resulted in a 189 bp product, whereas amplification of genomic DNA generated a 356 bp product (Fig. 3A). RT-PCR of total RNA extracted from zebrafish 3 days after injection with MO1 revealed that essentially all (>90%) of the pre-mRNA remained unprocessed, attesting to the efficiency of the morpholino knockdown (Fig. 3A). Injection of control morpholinos, either a global standard control MO (scMO) or 5-bp mismatched control (cMO), had no effect on pre-mRNA processing (Fig. 3A).

The effect of the injection of morpholinos into one- to four-cell embryos was first examined by determining the survival of the embryos. Of the 180 embryos injected with *abca12* MO1, 76% survived at 3 dpf, a number that did not statistically differ from the survival of embryos injected with standard control morpholino (81%) (Table 1). At 5 dpf, the survival of embryos injected with MO1 was only 6%, a statistically significant reduction from the survival noted with scMO and uninjected controls (81% and 87%, respectively;  $P < 0.0001$ ) (Table 1).



**Fig. 3. Knockdown of *abca12* and *snap29* expression by morpholinos.** (A) Knockdown of *abca12*. (B) Knockdown of *snap29*. MO1 and MO2 morpholinos (right lanes, the upper panel), which target the splice donor site at the exon-4–intron-4 border of the corresponding genes, prevents pre-mRNA splicing. The consequences of MO1 on *abca12* pre-mRNA splicing and MO2 on *snap29* mRNA splicing were determined by RT-PCR. The results showed the retention of intron 4 in the majority of mRNA transcripts (>90%) as compared with the normally transcribed control. The mRNA levels were normalized by the level of  $\beta$ -actin mRNA (lower panels). cDNA and gDNA represent amplification of the corresponding complementary DNA and genomic DNA, respectively. Injections with the 5-bp mismatched control morpholino for *abca12* (cMO) or global standard control morpholino (scMO) did not alter pre-mRNA processing, similar to the uninjected controls or those injected with phenol red.

Examination of the morphology of zebrafish larvae injected with MO1 ( $n=180$ ) revealed profound changes during development. Although no differences were noted between the morphant and control larvae at 1 dpf, by 3 dpf the morphants had developed noticeable changes in the distribution of pigment along their trunk and tail, in addition to pericardial edema (Fig. 4A). Upon careful examination at 3 dpf, 92% of larvae displayed yolk sac enlargement and severe disruption of their chromatophore distribution, with 75% exhibiting concomitant pericardial edema (Table 1).

#### Altered epidermal morphology in the morphant larvae

To examine the consequences of the morpholino-mediated knockdown of *abca12* expression in the skin of zebrafish, we first used scanning electron microscopy (SEM) to examine the surface

contour and cellular morphology of the epidermis. In 3-dpf controls ( $n=21$ ), well-demarcated keratinocytes with distinct borders and characteristic microridges were observed (Fig. 5). Examination of the skin surface of the morphant larvae ( $n=4$ ) revealed perturbations in the architecture of the microridges, with spicules protruding from the center of each keratinocyte. Thus, the development of the top layer of skin during the first 3 days of zebrafish development was perturbed in the absence of Abca12 activity.

Alterations in the epidermis at 3 dpf were further examined by transmission electron microscopy (TEM) both in control and morphant larvae ( $n=4$  in each group). At this developmental stage, normal epidermis consists of two unicellular layers, the superficial layer and the basal layer. The contour of the outer surface of the superficial layer is studded with spicules that correspond to the microridges noted previously on SEM (Fig. 6A). The epidermis rests on a basement membrane, which separates the epidermis from the underlying developing dermis.

The epidermis of the morphant larvae similarly consisted of two cell layers resting on a basement membrane (Fig. 6B). However, in contrast to the control larvae, both layers of the morphant epidermis contained an abundance of electron-dense granules, approximately 440 nm in average diameter. Closer examination of these aggregates at higher magnification suggested the presence of lipid-like vesicles within the larger electron-dense granules (Fig. 6C,D). It should be noted that, although somewhat similar aggregates of electron-dense material were noted in the epidermis of the control specimens, they were localized only to the area of the superficial layer just below the microridges.

#### Co-injection of human *ABCA12* mRNA rescues the morpholino-mediated phenotype

To test the specificity of the phenotypic changes associated with MO1 injection, a rescue experiment with co-injection of in vitro transcribed human *ABCA12* mRNA was performed. The injection of MO1 alone caused characteristic phenotypic changes, whereas co-injection of human mRNA together with MO1 partially rescued the phenotype (Fig. 4A,B). Specifically, at 5 dpf, the survival of the co-injected larvae was 62%, which is statistically different from the 6% in those injected with MO1 alone ( $P<0.0001$ ) (Table 1). Also, 27% of co-injected larvae ( $n=184$ ) had a phenotype that was indistinguishable from the controls. In the remaining 73% of co-injected larvae, the degree of yolk sac enlargement and chromatophore disorganization was noticeably less than in the larvae injected with MO1 alone. Of this 73%, 70% also manifested

**Table 1. Survival and development of phenotype in zebrafish injected with *abca12* morpholino**


Experimental group	No. of fish	3 dpf			5 dpf		
		Survival (%)	Skin phenotype (%)	Edema (%)	Survival (%)	Skin phenotype (%)	Edema (%)
Uninjected control	152	87	0	0	87	0	0
scMO	177	81	0	0	81	0	0
<i>abca12</i> MO1	180	76	92 <sup>a</sup>	75 <sup>a</sup>	6 <sup>a</sup>	0	0
<i>abca12</i> MO1+ hABCA12 mRNA	184	87 <sup>b</sup>	81 <sup>b</sup> (milder)	74 (milder)	62 <sup>c</sup>	73 <sup>c</sup> (milder)	70 <sup>c</sup> (milder)

This is a representative experiment in which all groups were followed in parallel. Similar results were obtained in >ten additional experiments with the same design. Skin phenotype refers to epidermal perturbations, disruption of the chromatophore distribution and yolk sac enlargement. Edema is pericardial edema.

scMO, standard control morpholino with no biological function and no target sequence in zebrafish genome (Robu et al., 2007).

<sup>a</sup>Statistical significance between the *abca12* MO1 group and scMO group (Fisher's exact test:  $P<0.0001$ ).

<sup>b,c</sup>Statistical significance between the *abca12* MO1 group and the *abca12* MO1+hABCA12 mRNA group (Fisher's exact test: <sup>b</sup> $P<0.05$ ; <sup>c</sup> $P<0.0001$ ).



**Fig. 4. Zebrafish phenotypes and their mRNA rescue at 3 dpf.**

(A) Phenotypic appearance of zebrafish larvae after injection with an *abca12* MO1 morpholino (middle panel) compared with control larvae (left panel), and partial rescue with human *ABCA12* mRNA (right panel). (B) Higher magnification of the larvae shown in A. (C) Phenotype of larvae at 3 dpf injected with *snap29* morpholinos MO2 or MO3. The irregular contour of the epidermis is noted by arrows.

pericardial edema. The rescue experiment, in addition to injection of control morpholinos, attested to the specificity of the phenotype documented in the morphant larvae. These experiments also confirmed that the zebrafish *abca12* gene is the functional homolog of human *ABCA12*.

#### Epidermal perturbations in zebrafish injected with *snap29* morpholino

Because knockdown of *abca12* expression was speculated to interfere with lipid secretion by lamellar granules, resulting in a characteristic epidermal phenotype, we proceeded to test this postulate by interfering with the lipid transport by another, independent

mechanism: knockdown of the expression of the *snap29* gene. The corresponding protein, Snap29, has been suggested to mediate lipid transport within the epidermis and the deficiency of SNAP29 expression results in syndromic ichthyosis in patients with CEDNIK syndrome (Rapaport et al., 2010; Sprecher et al., 2005).


Surveying the zebrafish genome database revealed the presence of one *SNAP29*-related gene, *snap29*, on chromosome 8. This gene product had 52% identity with the human gene product at the protein level, and cladogram and syntenic analyses suggested that zebrafish *snap29* is the ortholog of human *SNAP29* (Fig. 1C). The expression of the gene was readily detectable at 2 dpf by RT-PCR and the expression level increased during 3–8 dpf (Fig. 2C). In situ hybridization of larvae showed weak, ubiquitous expression with accentuation of the labeling in the central nervous system marginal zone (not shown).

Injection of a morpholino (MO2) placed on the exon-4–intron-4 junction of the *snap29* gene into one- to four-cell-stage embryos inhibited the processing of pre-mRNA by >90% (Fig. 3B). A second, non-overlapping morpholino (MO3), placed on the intron-4–exon-5 border of the *snap29* gene similarly resulted in >90% inhibition of the splicing of intron 4 (data not shown). Examination of the morphant larvae at 3 dpf ( $n=165$  for MO2, and  $n=203$  for MO3) revealed a phenotype consisting of pigmentary changes, somewhat analogous with those noted with the *abca12* morpholino, in 80% of larvae, and the contour of the epidermis in the tail section was irregular (Fig. 4C). SEM of 20 morphant larvae revealed perturbations in the morphology of the epidermis that were very similar to those noted as a result of *abca12* knockdown (Fig. 5). Examination of the epidermis of the *snap29* morphant larvae ( $n=4$ ) by TEM at 3 dpf revealed an increase in vesicles, which appeared empty under the same fixation conditions that revealed accumulation of lipid-like material in *abca12* morphant fish (Fig. 6E,F). Thus, interference by morpholino knockdown of the expression of two independent genes, *abca12* and *snap29*, that are involved in lipid transport in the epidermis can lead to similar phenotypic alterations in the epidermal morphology.


#### DISCUSSION

##### *ABCA12* mutations underlie HI

The molecular basis of HI is linked to mutations in the *ABCA12* gene (Akiyama et al., 2005; Kelsell et al., 2005). Initial approaches utilizing single-nucleotide polymorphism-based chip technology and homozygosity mapping of families with individuals affected with HI placed the candidate gene locus on chromosomal region 2q35, and microsatellite markers narrowed the interval to consist of six genes (Kelsell et al., 2005). Several previous observations pointed to *ABCA12* as a candidate gene within the critical region. First, a characteristic ultrastructural feature of the epidermis in HI is an abnormality in the



**Fig. 5. SEM of the skin surface.** The skin of the tail of the control larvae injected with the global standard control morpholino at 3 dpf shows the presence of keratinocytes with well-demarcated cell-cell borders (arrowhead) containing microridges (star; left panel). The morphant larvae injected with MO1 morpholino for *abca12* (middle) or *snap29* (MO2; right panel) revealed perturbed microridge formation with spicules in the center of the keratinocytes.



**Fig. 6. TEM of 3-dpf larvae injected with *abca12* or *snap29* morpholinos.** (A,E) Control morpholino (scMO); (B) *abca12* morpholino (MO1). Boxes surrounding electron-dense subcellular structures in B were examined at higher magnification and are shown in C and D. (F) Injection with *snap29* morpholino (MO2). (A-F) Arrows point to microridges; open arrowheads indicate basement membrane; solid black arrowheads point to the areas of accumulation of putative lipids within the electron-dense granules in C and D; solid white arrowheads in F point to apparently empty vesicles. e, epidermis; d, developing dermis.

localization of epidermal lipids, together with abnormal ultrastructural epidermal lamellar granules (Akiyama, 2006b). *ABCA12* has been suggested to encode a transmembrane transporter protein, which, from sequence homology with several other ABC family members, was thought to be involved in the transport of lipids (Kaminski et al., 2006). Second, the *ABCA12* gene was previously shown to harbor missense mutations in a milder form of ichthyosis, lamellar ichthyosis type 2 (LI2), with some resemblance to the phenotype in patients with HI who survive beyond the immediate postnatal period (Lefèvre et al., 2003). Currently, a total of 53 distinct mutations have been identified in the *ABCA12* gene (Akiyama, 2010).

Expression of *ABCA12* has been localized to lamellar granules. In normal epidermal keratinocytes there is an upregulation of *ABCA12* expression in association with physiological keratinization of the human epidermis (Sakai et al., 2007). Mutations in the *ABCA12* gene result in congested lipid retention in the skin of individuals with HI. It has been suggested that *ABCA12* transports ceramides, the major lipid of the stratum corneum of the epidermis. Finally, lamellar-granule-mediated lipid secretion was resumed in the cultured keratinocytes of patients with HI upon transfer of the wild-type *ABCA12* gene (Akiyama et al., 2005). Thus, it is clear that mutations in the *ABCA12* transporter gene underlie HI.

#### *abca12* and zebrafish skin development

In this study, we have demonstrated that zebrafish *abca12* is the ortholog of human *ABCA12*. There is a high degree of conservation of the Walker A and B motifs in addition to the retention of the four transmembrane domains containing one, five, one and five

transmembrane segments, respectively. Zebrafish NBF1 and NBF2 domains in the *Abca12* protein have 74% and 68% similarity with human NBF1 and NBF2 domains, respectively, at the amino acid level.

Whole-mount in situ hybridization in developing zebrafish embryos revealed that *abca12* was expressed in the EVL and the periderm. The EVL first appears at the 64-cell stage of development (~2 hpf) and is the outermost monolayer of cells surrounding the embryo. The EVL eventually gives rise to the periderm, which is thought to ultimately be replaced by the superficial stratum of the epidermis (Kimmel et al., 1995; Le Guellec et al., 2004). Although the physiology of zebrafish skin is still largely unexplored, the fact that *abca12* is expressed in the skin suggests its importance in normal skin development. This hypothesis is further strengthened by the results from our morpholino experiments. Injecting a morpholino that inhibited pre-mRNA splicing by >90% produced alterations in chromatophore distribution and the abnormal retention of lipids in both layers of the epidermis. Not only does this suggest that *abca12* is responsible for lipid transport in zebrafish, but the abnormal accumulation of lipids throughout the epidermis is a frequent finding in individuals with HI. Finally, the rescue of this phenotype by co-injection of human *ABCA12* mRNA shows that the phenotype is the result of *abca12* knockdown and not due to an off-target effect. In this context, it should be emphasized that the EVL-derived skin in zebrafish is embryologically different from the mammalian skin. Specifically, zebrafish epidermis does not undergo terminal differentiation, which in human skin culminates in the development of stratum corneum with barrier function. Emphasizing this



difference is the fact that survey of the current zebrafish genome database (Ensembl, Zebrafish Zv9; [http://www.ensembl.org/Danio\\_erio/Info/Index](http://www.ensembl.org/Danio_erio/Info/Index)) does not reveal the presence of filaggrin, involucrin and trichohyalin genes, which are crucial for development of the stratum corneum in human epidermis (Li et al., 2011).

The role of lipids in epidermal development is further emphasized by our findings that knockdown of the expression of an independent gene, *snap29*, results in a similar epidermal phenotype as noted in *abca12* mutant larvae. *Snap29* has been postulated to mediate lipid transport in the epidermis by facilitating membrane fusion of lamellar granules (Sprecher et al., 2005). Thus, interference of lipid trafficking by knockdown of two independent genes results in phenocopies of the epidermal perturbations in zebrafish, mimicking epidermal alterations in different forms of ichthyosis. It should be noted that, similar to the CEDNIK syndrome, ichthyosis has been reported in association with mental retardation, enteropathy, deafness, peripheral neuropathy and keratoderma, dubbed as the MEDNIK syndrome (Montpetit et al., 2008). This constellation was shown to be associated with a homozygous splice-site mutation in the *AP1S1* gene, encoding a subunit of the adaptor protein complex that regulates clathrin-coated vesicle assembly, protein cargo sorting, and vesicular trafficking between organelles in eukaryotic cells (Montpetit et al., 2008). The pathogenic effect of this mutation was validated by knockdown of *ap1s1* expression in zebrafish by a morpholino, resulting in perturbation in skin formation, reduced pigmentation and motility deficits. These findings, together with our observations in *snap29* mutant larvae, attest to the importance of vesicular trafficking in epidermal morphogenesis.

As indicated by morphological observations of the developing epidermis in zebrafish in comparison with human skin, there are clear differences. For example, the embryological origin of the EVL (periderm) in zebrafish is distinct from the basal layer in embryonic skin. In spite of this difference, there is an increasing body of evidence suggesting that the underlying molecular differentiation pathways are conserved between mammals and the zebrafish epidermis, based on molecular homologies (Sabel et al., 2009; Slanchev et al., 2009). Our work highlighting the early *abca12* expression in the EVL seems to support the conclusions that EVL forms the external layer of the embryonic and larval dermis and represents the initial differentiation of a true epidermis (Fukazawa et al., 2010).

Collectively, our results highlight the role of lipid transport and vesicular trafficking in epidermal development, and the results further suggest that zebrafish can serve as a model system to study different variants of ichthyosis, such as HI and the CEDNIK syndrome. Besides increasing our understanding of the disease mechanisms involved in ichthyotic syndromes, this model system is potentially useful for testing novel treatment modalities, for example by performing a small molecule library screen for compounds that are able to suppress the phenotype.

## METHODS

### Maintenance of zebrafish

Adult wild-type zebrafish were maintained under standard conditions at 28.5°C. Zebrafish embryos and larvae were also maintained at 28.5°C in a special embryo medium. All animals were housed in the zebrafish facility at Thomas Jefferson University and were cared for and used in accordance with University Institutional Animal Care and Use Committee guidelines and permission.

### Phylogenetic and syntenic analyses

The genomic sequences of zebrafish were extracted from the Ensembl database. The zebrafish protein sequences were aligned with the corresponding proteins in different species by using ClustalW software (<http://www.ebi.ac.uk/clustalw/>).

The accession numbers for the *abca12* gene products in different species are: *E. caballus* (ENSECAP00000007797), *C. lupus familiaris* (XP\_536058), *B. taurus* (XP\_001788086), *H. sapiens* (NP\_775099), *P. troglodytes* (XP\_516070), *M. musculus* (XP\_001002308), *R. norvegicus* (XP\_237242), *G. gallus* (XP\_421867), *D. rerio* (XP\_686632) and *O. latipes* (ENSORLP00000020129). The accession numbers for *ABCC10* in *H. sapiens* is NP\_258261. The accession numbers for *Abcc6* in different species are: *M. musculus* (NP\_061265), *H. sapiens* (NP\_001162), *D. rerio* (ENSARP00000065432), *T. nigroviridis* (ENSTNIP00000015029) and *T. rubripes* (ENSTRUP00000029065).

The accession numbers for the *snap29* gene products in different species are: *H. sapiens* (NP\_004773.1), *P. troglodytes* (XP\_514997.2), *M. mulatta* (XP\_001086227.1), *M. musculus* (NP\_075837.3), *R. norvegicus* (NP\_446262.3), *C. familiaris* (XP\_543568.2), *B. taurus* (NP\_001069427.1), *G. gallus* (NP\_001025823.1), *D. rerio* (XP\_700124.3), *S. salar* (NP\_001134759.1), *X. laevis* (NP\_001080076.1) and *A. thaliana* (NP\_196405.1).

Phylogenetic analyses were conducted in the Molecular Evolution Genetics Analysis software (MEGA) version 4.0 (Tamura et al., 2007). The cladogram was constructed using the Neighbor-Joining method (Saitou and Nei, 1987). The Kimura two-parameter method was used to compute the evolutionary distances (Zuckerkandl and Pauling, 1965). The statistical reliance of NJ tree branches was evaluated using 1000 bootstrap samples.

For syntenic analysis, the orientation and chromosomal positions of *abca12* and *snap29* and their adjacent genes were determined manually from the gene orientations in the current Ensembl database. The zebrafish (Zv9), human (GRCh37/hg19), mouse (NCB137/mm9) and chicken (WUGSC2.1/galGal3) genome assembly versions were used for this analysis.

### In situ hybridization

Whole-mount in situ hybridization was performed as described previously (Thisse and Thisse, 2008). Collected zebrafish embryos were fixed in 4% paraformaldehyde before hybridization. Digoxigenin (DIG)-labeled antisense and sense probes were synthesized. After hybridization, detection was performed with an anti-DIG antibody coupled to alkaline phosphatase.

### Morpholinos and microinjection

Morpholino oligonucleotides were obtained from Gene Tools, LLC (Corvallis, OR). The morpholino oligomer sequences were written from 5' to 3', to correspond to the following genomic sequences (brackets surround the morpholino target sequence, exon sequences are capitalized, intron sequences are in lowercase, and nucleotide substitutions are bolded). For *abca12* knockdown: splice donor site morpholino (MO1), tgggaataaatgtaattacgtg, targets the exon-4–intron-4 junction, AAATGAAATAACTGA[ACAGgtaattacattttccca]acggtc; 5-base pair mismatched control morpholino for *abca12* (cMO): tggcaaaaaatctaattacgtct. For *snap29* knockdown: splice donor site morpholino (MO2), ctgctctgtgttctcaccaggt, targets the exon-4–intron-4 junction,

GACAGAA[ACCTGGgtgagaaacacaagacag]cttctctcata; a second *snap29* splice junction morpholino (MO3) targets the intron 4-exon 5 border, ctcatctggaggacacaaacacaca, agtgtgtgtg[tgtgtg-tttgtgtctccagATGAG]ATGTCTCTGGGTC. Global standard control morpholino (scMO), cctcttacctcagttacaattata, has no target sequence in the zebrafish genome and is, therefore, inactive.

Embryos at the one- to four-cell stage were injected with an *abca12* morpholino (MO1, 25.6 ng) or *snap29* morpholinos (MO2, 2.6 ng and MO3, 5.2 ng) using glass microelectrodes fitted to a gas pressure injector (PL1-100, Harvard Apparatus). Electrodes were pulled (P-97, Flaming/Brown) and filled with morpholino and phenol red (final concentration 0.025%) to visualize the injected embryos. The embryos were then followed for viability, morphology and mRNA expression levels.

#### Total RNA isolation and cDNA synthesis

Zebrafish embryos were collected at 0 as well as 6 hpf and 1-8 dpf. They were disintegrated by pipetting through a 21 gauge needle and total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). To remove contaminating genomic DNA, RNase-free DNase I digestion (Fisher Scientific, St Louis, MO) was performed. 1 µg of total RNA was reverse transcribed using the Superscript III First-Strand cDNA synthesis kit (Invitrogen) according to the manufacturer's protocol. Controls were performed by omitting the reverse transcriptase enzyme. All cDNA samples were stored at -20°C for future use.

#### PCR amplification of cDNA

*abca12* cDNA was amplified by PCR using a forward primer on exon 4 (5'-ATCTGGGCAACTTGGGCAACT-3'), and a reverse primer on exon 5 (5'-TCATCTGGTCAGCAGTTCCAGAGA-3'). The *snap29* cDNA was amplified using a forward primer on exon 4 (5'-TTCTGCTGCTCTTGATAACGGCT-3'), and a reverse primer on exon 5 (5'-TTTAAGGCTTTTGGAGCTGCCGGTT-3'). Primers for the zebrafish *β-actin* gene (fwd: 5'-ATCTGGCACACACCTTCTACAATG; rev: 5'-GGGGTG-TTGAAGGCTCAAACATGAT) were used as a positive control. PCR was performed using Taq polymerase and Q buffer (Qiagen, Valencia, CA), according to the manufacturer's instructions. The PCR conditions were as follows: an initial denaturation at 94°C for 5 minutes, followed by 35 cycles of 94°C for 1 minute; 58°C for 1 minute; 72°C for 1 minute; and finally 72°C for 10 minutes. The intensity of the bands was quantified using ImageQuant version 5.0 software (Molecular Dynamics, Sunnyvale, CA).

#### mRNA rescue experiments

Capped full-length human mRNA corresponding to *ABCA12* was transcribed from an expression vector pCMV-Tag4B using the T3 mMessage mMachine kit (Ambion, Austin, TX). The morpholino was injected into one- to four-cell-stage embryos either alone or in combination with mRNA (2.3 ng) and followed for viability and morphology.

#### Scanning electron microscopy

Samples were fixed in neutral buffered formalin at room temperature for 2 hours, followed by a rinse with phosphate buffered saline and an ethanol dehydration series of exchanges by completely replacing each successively higher ethanol solution with

## TRANSLATIONAL IMPACT

### Clinical issue

Ichthyosis comprises a group of cutaneous disorders characterized by dry, scaly skin and a broad spectrum of other phenotypic manifestations. One of the most severe forms of ichthyosis is known as harlequin ichthyosis (HI); neonates affected with HI are born encased in a thick skin that restricts their movement and frequently die shortly after birth. Some forms of ichthyosis are syndromic; for example, CEDNIK syndrome is so-named because it consists of cerebral dysgenesis, neuropathy, ichthyosis and keratoderma. Details of the pathomechanisms of HI have recently been revealed through molecular genetics, which showed that patients with this disorder carry mutations in the *ABCA12* gene. Examination of *Abca12*<sup>-/-</sup> mice suggested that this gene encodes a transmembrane transporter present in the epidermis that is postulated to transport lipids (specifically ceramides) and that is required for formation of the stratum corneum on the surface of the skin. Although the mouse model is useful in that it recapitulates features of human HI, drawbacks include the long gestational period and the small number of offspring produced per litter. CEDNIK syndrome is caused by mutations in the *SNAP29* gene, which is required for normal vesicle trafficking and lipid transport in the epidermis. There is no animal model for this syndrome.

### Results

To create alternative, more expedient model systems to investigate pathological mechanisms of both HI and CEDNIK syndrome, the authors of this study knocked down the homologs of *ABCA12* and *SNAP29* in zebrafish embryos (*Danio rerio*). Morpholino antisense oligonucleotides targeted to exon-intron splice junctions were used to inhibit the splicing of *abca12* or *snap29* pre-mRNA. Inhibition of processing of either one of these mRNAs was accompanied by changes in the distribution of pigment along the trunk and tail of the fish as early as 2 days post-fertilization (dpf). Examination of epidermal morphology by scanning electron microscopy revealed perturbations in the surface contour of the keratinocytes, with loss of characteristic microridges and development of pathological spicules protruding from the center of each keratinocyte. These epidermal changes were accompanied by premature demise of the fish by 5 dpf. Transmission electron microscopy revealed an abundance of electron-dense granules in both morphants: lipid-like vesicles were seen in *abca12* knockdown fish, whereas the epidermis of *snap29* knockdown animals showed the presence of apparently empty vesicles.

### Implications and future directions

This study demonstrates that inhibition of *abca12* or *snap29* gene splicing in zebrafish leads to epidermal perturbations that are similar to those seen in human patients with various forms of ichthyosis. In addition, it suggests that interfering with two independent pathways involved in lipid transport can result in phenotypically similar perturbations in epidermal morphogenesis. These systems can serve as models to study ichthyosis, and provide a means to develop pharmacological approaches towards treatment of this currently intractable group of diseases. Finally, in a broader sense, this study attests to the feasibility of using zebrafish as a model system to study heritable skin diseases.

the next higher (20, 30, 50, 75, 95 and 100%). Samples were then incubated for 15 minutes in a 1.5 ml micro test tube containing 1,1,2-Trichloro-1,2,2-trifluoroethane before covering the open micro test tube with parafilm, punching holes in it with a 30G needle, and situating it under a fume hood where it was dried by turbulent air flow. Samples were then mounted onto stubs with carbon paint and coated in 50 nm of gold using a sputter coater. Specimens were imaged in a JEOL-T330A scanning electron microscope (JEOL, Tokyo, Japan) at 15 kV.



### Transmission electron microscopy

Samples were collected and fixed overnight at 4°C in 2.5% glutaraldehyde, 2% paraformaldehyde and 0.1 M sodium cacodylate. Samples were then washed in 0.1 M sodium cacodylate before undergoing secondary fixation in 2% osmium tetroxide, 1.5% potassium ferricyanide and 0.1 M sodium. Samples were again washed with 0.1 M sodium cacodylate followed by deionized water before undergoing en block staining with 2% uranyl acetate. Samples were washed again with deionized water, then dehydrated in a graded ethanol series and embedded in EMBED-812 (EMS, Hatfield, PA). Ultrathin sections (60 nm) were cut and analyzed using a JEOL JEM-1010 transmission electron microscope fitted with a Hamamatsu digital camera (Hamamatsu Photonics, Hamamatsu City, Japan) and AMT Advantage image capture software (AMT, Danvers, MA).

### Statistical analysis

Risk differences and 95% confidence intervals were calculated between experimental groups with regards to survival, skin phenotype and edema in Table 1, for 3 dpf and 5 dpf separately. Fisher's exact test was used to determine the difference between proportions because of the presence of cells with zero observations. Adjustments for multiple comparisons were performed using False Discovery Rate, and it is these adjusted *P*-values that are reported. Analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC).

### ACKNOWLEDGEMENTS

The authors thank the following colleagues for advice and assistance: Wolfgang Driever, Institute for Biology I, University of Freiburg; Raymond Meade, Biomedical Imaging Core Facility, University of Pennsylvania; Gerald Harrison, Department of Biochemistry, School of Dental Medicine, University of Pennsylvania; Jean-Yves Sire, Equipe "Evolution et Développement du Squelette", Université Paris; Eijiro Adachi, Department of Matrix Biology and Tissue Regeneration, Graduate School of Medical Sciences, Kitasato University; Ulrich Rodeck, Gabor Kari, April Aguilard, Adele Donahue and Andrzej Fertala, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University; Terry Hyslop and Jocelyn Andrei, Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University. Carol Kelly assisted in manuscript preparation. This study was supported by the NIH/NIAMS grant R01AR055225 to J.U.; by the University of Virginia to C.T. and B.T. Q.L. is a recipient of a Research Career Development Award from the Dermatology Foundation.

### COMPETING INTERESTS

The authors declare that they do not have any competing or financial interests.

### AUTHOR CONTRIBUTIONS

Q.L., M.F., C.T. and B.T. performed the experiments; M.A. provided reagents; H.S. and E.S. interpreted the data and edited the manuscript; S.-Y.H. contributed to the data analysis; J.U. developed the concept, interpreted the data and prepared the manuscript.

### REFERENCES

- Akiyama, M.** (2006a). Harlequin ichthyosis and other autosomal recessive congenital ichthyoses: the underlying genetic defects and pathomechanisms. *J. Dermatol. Sci.* **42**, 83-89.
- Akiyama, M.** (2006b). Pathomechanisms of harlequin ichthyosis and ABCA transporters in human diseases. *Arch. Dermatol.* **142**, 914-918.
- Akiyama, M.** (2010). ABCA12 mutations in harlequin ichthyosis, congenital ichthyosiform erythroderma and lamellar ichthyosis. *Hum. Mutat.* **31**, 1090-1096.
- Akiyama, M., Sugiyama-Nakagiri, Y., Sakai, K., McMillan, J. R., Goto, M., Arita, K., Tsuji-Abe, Y., Tabata, N., Matsuoka, K. and Sasaki, R.** (2005). Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. *J. Clin. Invest.* **115**, 1777-1784.
- Brown, S. J. and Irvine, A. D.** (2008). Atopic eczema and the filaggrin story. *Semin. Cutan. Med. Surg.* **27**, 128-137.
- Brown, S. J. and McLean, W. H. I.** (2008). Eczema genetics: current state of knowledge and future goals. *J. Invest. Dermatol.* **129**, 543-552.
- Elias, P. M., Crumrine, D., Rasser, U., Hachem, J. P., Menon, G. K., Man, W., Choy, M. H., Leyboldt, L., Feingold, K. R. and Williams, M. L.** (2004). Basis for abnormal

desquamation and permeability barrier dysfunction in RXLI. *J. Invest. Dermatol.* **122**, 314-319.

- Fuchs-Telem, D., Stewart, H., Rapaport, D., Nousbeck, J., Gat, A., Gini, M., Lugassy, Y., Emmert, S., Eckl, K., Hennies, H. C. et al.** (2011). CEDNIK syndrome results from loss-of-function mutations in SNAP29. *Br. J. Dermatol.* **164**, 610-616.
- Fukazawa, C., Santiago, C., Park, K. M., Deery, W. J., Gomez de la Torre Canny, S., Holterhoff, C. K. and Wagner, D. A.** (2010). poly/chuk/ikk1 is required for differentiation of the zebrafish embryonic epidermis. *Dev. Biol.* **346**, 272-283.
- Kaminski, W. E., Piehler, A. and Wenzel, J. J.** (2006). ABC A-subfamily transporters: structure, function and disease. *Biochim. Biophys. Acta* **1762**, 510-524.
- Kari, G., Rodeck, U. and Dicker, A. P.** (2007). Zebrafish: an emerging model system for human disease and drug discovery. *Clin. Pharmacol. Ther.* **82**, 70-80.
- Kelsell, D. P., Norgett, E. E., Unsworth, H., Teh, M. T., Cullup, T., Mein, C. A., Dopping-Hepenstal, P. J., Dale, B. A., Tadini, G. and Fleckman, P.** (2005). Mutations in ABCA12 underlie the severe congenital skin diseases harlequin ichthyosis. *Am. J. Hum. Genet.* **76**, 794-803.
- Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. and Schilling, T. F.** (1995). Stages of embryonic development of the zebrafish. *Dev. Dyn.* **203**, 253-310.
- Le Guellec, D., Morvan-Dubois, G. and Sire, J. Y.** (2004). Skin development in bony fish with particular emphasis on collagen deposition in the dermis of the zebrafish (*Danio rerio*). *Int. J. Dev. Biol.* **48**, 217-232.
- Lefèvre, C., Audebert, S., Jobard, F., Bouadjar, B., Lakhdar, H., Boughdene-Stambouli, O., Blanchet-Bardon, C., Heilig, R., Foglio, M. and Weissenbach, J.** (2003). Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. *Hum. Mol. Genet.* **12**, 2369-2378.
- Li, Q., Frank, M., Thisse, C., Thisse, B. and Uitto, J.** (2011). Zebrafish: a model system to study heritable skin diseases. *J. Invest. Dermatol.* **131**, 565-571.
- McGrath, J. A. and Uitto, J.** (2008). The filaggrin story: novel insights into skin-barrier function and disease. *Trends Mol. Med.* **14**, 20-27.
- Montpetit, A., Côté, S., Brusteine, E., Drouin, C. A., Lapointe, L., Boudreau, M., Meloche, C., Drouin, R., Hudson, T. J., Drapeau, P. et al.** (2008). Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. *PLoS Genet.* **4**, e1000296.
- Rapaport, D., Lugassy, Y., Sprecher, E. and Horowitz, M.** (2010). Loss of SNAP29 impairs endocytic recycling and cell motility. *PLoS ONE* **5**, e9759.
- Sabel, J. L., d'Alençon, C., O'Brien, E. K., Van Otterloo, E., Lutz, K., Cuykendall, T. N., Schutte, B. C., Houston, D. W. and Cornell, R. A.** (2009). Maternal interferon regulatory factor 6 is required for the differentiation of primary superficial epithelia in *Danio* and *Xenopus* embryos. *Dev. Biol.* **325**, 249-263.
- Saitou, N. and Nei, M.** (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol. Biol. Evol.* **4**, 406-425.
- Sakai, K., Akiyama, M., Sugiyama-Nakagiri, Y., McMillan, J. R., Sawamura, D. and Shimizu, H.** (2007). Localization of ABCA12 from golgi apparatus to lamellar granules in human upper epidermal keratinocytes. *Exp. Dermatol.* **16**, 920-926.
- Slanchev, K., Carney, T. J., Stemmler, M. P., Koschorz, B., Amsterdam, A., Schwarz, H. and Hammerschmidt, M.** (2009). The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development. *PLoS Genet.* **5**, e1000563.
- Smyth, I., Hacking, D. F., Hilton, A. A., Mukhamedova, N., Meikle, P. J., Ellis, S., Satterley, K., Collinge, J. E., de Graaf, C. A. and Bahlo, M.** (2008). A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis. *PLoS Genet.* **4**, e1000192.
- Sprecher, E., Ishida-Yamamoto, A., Mizrahi-Koren, M., Rapaport, D., Goldsher, D., Indelman, M., Topaz, O., Chefetz, I., Keren, H., O'Brien, T. J. et al.** (2005). A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma. *Am. J. Hum. Genet.* **77**, 242-251.
- Sundberg, J. P., Boggess, D., Hogan, M. E., Sundberg, B. A., Rourk, M. H., Harris, B., Johnson, K., Dunstan, R. W. and Davison, M. T.** (1997). Harlequin ichthyosis (ichq): a juvenile lethal mouse mutation with ichthyosiform dermatitis. *Am. J. Pathol.* **151**, 293-310.
- Tamura, K., Dudley, J., Nei, M. and Kumar, S.** (2007). MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. *Mol. Biol. Evol.* **24**, 1596-1599.
- Thisse, C. and Thisse, B.** (2008). High resolution in situ hybridization on whole-mount zebrafish embryo. *Nat. Protoc.* **3**, 59-69.
- Tusnády, G. E., Sarkadi, B., Simon, I. and Váradi, A.** (2006). Membrane topology of human ABC proteins. *FEBS Lett.* **580**, 1017-1022.
- Yanagi, T., Akiyama, M., Nishihara, H., Sakai, K., Nishie, W., Tanaka, S. and Shimizu, H.** (2008). Harlequin ichthyosis model mouse reveals alveolar collapse and severe fetal skin barrier defects. *Hum. Mol. Genet.* **17**, 3075-3083.
- Zuckerklund, E. and Pauling, L.** (1965). Evolutionary divergence and convergence in proteins. In *Evolving Genes and Proteins* (ed. V. Bryson and H. J. Vogel), pp. 97-166. New York: Academic Press.

thickness of the mucous layer of small intestines, resulting in the inhibition of small intestinal absorption.<sup>4</sup> In addition, PGE<sub>1</sub> increases blood flow in the stomach and upregulates the digestion in the stomach. During the provocation test in our case, serum gliadin levels were not increased by administering misoprostol. However, sodium cromoglicate, a mast cell stabilizer commonly used to treat allergic rhinitis, allergic conjunctivitis, and asthma, could not affect serum gliadin levels in the provocation test, and therefore allowed the symptoms to occur. We consider that the effects of misoprostol on the alimentary tract are crucial for the prevention of FDEIA. Our observation indicates that the exacerbating effect of aspirin in FDEIA comes from the inhibitory effects of aspirin on PGE<sub>1</sub> in the gastrointestinal milieu. Thus, misoprostol would be a promising prophylactic drug for FDEIA.

Aya Takahashi, MD  
Kimiko Nakajima, MD  
Mitsunori Ikeda, MD  
Shigetoshi Sano, MD  
Department of Dermatology  
Kochi Medical School, Nankoku  
Kochi  
Japan

#### Type XVII collagen ELISA indices significantly decreased after bullous pemphigoid remission

The major pathogenic epitope of bullous pemphigoid (BP) is known to be the noncollagenous extracellular domain (NC16A) of type XVII collagen (COL17).<sup>1</sup> Here we investigated indirect immunofluorescence (IIF) and COL17 NC16A domain enzyme-linked immunosorbent assay (ELISA)<sup>2-5</sup> data before treatment and after remission to evaluate the usefulness of ELISA analyses as indicators for BP disease activity.

We included ten consecutive BP patients [eight women and two men: between 33 and 80 years old (mean; 59 years old)] who showed typical clinical features before treatment and were successfully treated, resulting in complete or partial remission at our institute. The first day of each patient visit was within the last three years. In all patients, the diagnosis was confirmed by histopathological observation and immunofluorescence study, i.e. histopathological subepidermal blister formation was observed and direct and IIF studies revealed the presence of autoantibodies along the dermal-epidermal junction. All patients were successfully treated with oral prednisolone therapy of 30–50 mg/d with or without azathioprine or a combination therapy using tetracycline and nicotinamide. Treatment periods from initial diagnosis to remission ran-

Kunie Kohno, MD  
Eishin Morita, MD  
Department of Dermatology  
Shimane University Faculty of Medicine  
Izumo, Shimane  
Japan  
E-mail: jm-aya.derm@kochi-u.ac.jp

#### References

- 1 Matsuo H, Morita E, Tatham AS, *et al.* Identification of the IgE-binding epitope in omega-5 gliadin, a major allergen in wheat-dependent exercise-induced anaphylaxis. *J Biol Chem* 2004; 279: 12135–40.
- 2 Matsuo H, Morimoto K, Akaki T, *et al.* Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. *Clin Exp Allergy* 2005; 35: 461–6.
- 3 Sheffer AL, Tong AK, Murphy GF, *et al.* Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulation. *J Allergy Clin Immunol* 1985; 75: 479–84.
- 4 Gurleyik E, Coskun O, Ustundag N, *et al.* Prostaglandin E1 maintains structural integrity of intestinal mucosa and prevents bacterial translocation during experimental obstructive jaundice. *J Invest Surg* 2006; 19: 283–9.

ged from four months to 35 months (mean; 14.6 ± 10.8 months). Serum samples were obtained for ELISA and IIF at least twice during the disease course for each patient.

Concentration of autoantibodies in the patients' sera directed against the NC16A domain of COL17 was measured using the COL17 NC16A ELISA kit following the kit's instructions.<sup>6</sup> IIF staining and evaluation were performed as previously described using normal human skin as a substrate.<sup>7</sup>

In all the cases, the ELISA indices showed a decrease during the successful treatment course. ELISA indices after remission were significantly reduced compared with those before treatment ( $P < 0.0001$ ) (Fig. 1a). IIF titers also decreased after remission in six cases, but the titers were not apparently reduced in the other four cases, although a statistically significant reduction in combined IIF titer was observed after remission compared with those before treatment ( $P < 0.05$ ) (Fig. 1b).

Positive correlation between ELISA indices and BP disease activity has been reported previously in the literature. Di Zenzo *et al.*<sup>8</sup> demonstrated that disease severity before treatment was well correlated with ELISA indices in BP patients. Izumi *et al.*<sup>9</sup> described ELISA indices and alteration of disease activity of five BP patients during various treatments. In this study, we compared the ELISA